Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Rhea-AI Summary

Phathom Pharmaceuticals (Nasdaq: PHAT) announced a proposed underwritten public offering of common stock and, for some investors, pre-funded warrants, with underwriters granted a 30-day option to buy up to an additional 15% of the securities. The company said net proceeds are intended for general corporate purposes, including working capital, commercialization, and R&D. The offering is being made from a shelf registration that became effective on January 7, 2026. Guggenheim Securities and Cantor are joint bookrunning managers. There is no assurance the offering will be completed or on stated terms.

Positive

• Shelf registration became effective on January 7, 2026
• Proceeds earmarked for commercialization and R&D

Negative

• Proposed offering may cause shareholder dilution
• Underwriters' 30-day 15% overallotment could increase dilution
• No assurance the offering will be completed or sized

News Market Reaction – PHAT

-13.72%

37 alerts

-13.72% News Effect

+4.5% Peak Tracked

-12.1% Trough Tracked

-$205M Valuation Impact

$1.29B Market Cap

1.3x Rel. Volume

On the day this news was published, PHAT declined 13.72%, reflecting a significant negative market reaction. Argus tracked a peak move of +4.5% during that session. Argus tracked a trough of -12.1% from its starting point during tracking. Our momentum scanner triggered 37 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $205M from the company's valuation, bringing the market cap to $1.29B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Underwriter option period: 30 days Underwriter option size: 15% of securities offered

2 metrics

Underwriter option period 30 days Duration of option for underwriters to buy additional securities

Underwriter option size 15% of securities offered Potential additional amount of securities in the proposed offering

Market Reality Check

Price: $12.56 Vol: Volume 375,131 is below t...

low vol

$12.56 Last Close

Volume Volume 375,131 is below the 20-day average of 892,956 (relative volume 0.42x). low

Technical Price $16.37 is trading above the 200-day MA at $10.05.

Peers on Argus

PHAT was up 3.41% pre-announcement, while close peers showed mixed moves: IMNM a...

PHAT was up 3.41% pre-announcement, while close peers showed mixed moves: IMNM and PRAX were modestly positive, while EYPT, QURE, and URGN traded lower. This points to stock-specific dynamics rather than a broad biotechnology move.

Historical Context

5 past events · Latest: Nov 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 04	Clinical trial update	Positive	-1.8%	First patient dosed in Phase 2 VOQUEZNA EoE study with 2027 data goal.
Nov 03	Investor conferences	Positive	+1.3%	Management participation in multiple late-2025 healthcare investor conferences.
Oct 30	Quarterly earnings	Positive	-1.6%	Q3 2025 revenue growth, improved cash usage and guidance for 2025 revenue.
Oct 23	Medical meeting	Positive	+1.1%	VOQUEZNA to be highlighted at ACG 2025 with product theater and programs.
Oct 20	Earnings preview	Positive	+8.1%	Announcement of upcoming Q3 2025 results webcast and business update.

Pattern Detected

Recent news shows mixed reactions: several positive clinical and earnings updates saw both gains and sell-offs, indicating no consistent pattern of how PHAT trades around good news.

Recent Company History

Over the last few months, Phathom reported growing VOQUEZNA momentum, with Q3 2025 product revenue at $49.5M and guidance for $170–$175M 2025 revenue, while narrowing losses per the 10-Q. The company advanced its pipeline, dosing the first patient in a Phase 2 EoE trial with topline data expected in 2027, and highlighted VOQUEZNA at major GI meetings. Conference participation and earnings communications around late October–November 2025 produced both positive and negative one-day stock reactions, underscoring variable trading responses to fundamentally constructive updates.

Market Pulse Summary

The stock dropped -13.7% in the session following this news. A negative reaction despite the company...

Analysis

The stock dropped -13.7% in the session following this news. A negative reaction despite the company outlining standard use of proceeds for commercialization and R&D fits a common pattern where equity offerings are viewed as dilutive. PHAT’s history shows mixed price responses to positive news, suggesting sentiment can shift quickly. If selling intensifies beyond the initial reaction, it may reflect concerns about capital needs or execution rather than the mechanics of the offering alone.

Key Terms

pre-funded warrants, underwritten public offering, prospectus supplement, registration statement

4 terms

pre-funded warrants financial

"in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

underwritten public offering financial

"pre-funded warrants to purchase shares of its common stock, in an underwritten public offering."

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

prospectus supplement regulatory

"The proposed offering is being made only by means of a written prospectus, including a prospectus supplement"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

registration statement regulatory

"forming a part of an effective registration statement. A preliminary prospectus supplement"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

AI-generated analysis. Not financial advice.

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering. In addition, Phathom intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of the securities offered in the public offering. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering. 

Phathom intends to use the net proceeds from the proposed offering for general corporate purposes, including for working capital and commercialization and research and development expenses.

Guggenheim Securities and Cantor are acting as joint bookrunning managers for the proposed offering.

The securities described above are being offered by Phathom pursuant to a shelf registration statement that was filed with the Securities and Exchange Commission (SEC) on January 7, 2026 and became effective automatically upon filing. The proposed offering is being made only by means of a written prospectus, including a prospectus supplement, forming a part of an effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the proposed offering may be obtained from: Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Phathom
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA^® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA^® TRIPLE PAK^® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA^® DUAL PAK^® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults.

Forward-Looking Statements
Phathom cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements relating to the offering, including the timing of the offering and the anticipated use of the net proceeds therefrom and the grant of the option to purchase additional shares. The inclusion of forward-looking statements should not be regarded as a representation by Phathom that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed public offering, as well as risks and uncertainties inherent in Phathom’s business described in the Company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Phathom undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

CONTACTS

Media Contact:
Nick Benedetto
1-877-742-8466
media@phathompharma.com

Investor Contact:
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

FAQ

What is Phathom Pharmaceuticals (PHAT) offering in January 2026?

Phathom intends to offer common stock and, for some investors, pre-funded warrants in an underwritten public offering.

How large is the underwriter overallotment for PHAT's proposed offering?

Underwriters have a 30-day option to purchase up to an additional 15% of the securities offered.

What will PHAT use the net proceeds from the offering for?

Net proceeds are intended for general corporate purposes including working capital, commercialization, and R&D.

Who are the joint bookrunning managers for the PHAT offering?

Guggenheim Securities and Cantor are acting as joint bookrunning managers for the proposed offering.

Is the PHAT offering final and guaranteed to occur?

No; the company stated there is no assurance the proposed offering will be completed or on the terms described.

Where can investors get the PHAT preliminary prospectus supplement?

Copies will be available from Guggenheim or Cantor and electronically via the SEC website at www.sec.gov.